Skip to main content
Toggle navigation
Login
Home
Back
Favorite
0
Like
Facebook
Tweet
Session VII: Immune Checkpoint Inhibitors for NSCLC
Debate: How to Handle PD-L1 > 50%: Use Pembrolizumab + Histology Specific Chemo v Use Pembrolizumab Alone - Use Pembrolizumab + Histology Specific Chemo
Thursday, August 25, 2022
2:40 PM – 2:50 PM
Debate Speaker(s)
Aaron Lisberg, MD
University of California, Los Angeles